Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Ascentage Pharma Group Corp Limited has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners across 4 distinct art units, indicating that prosecution is distributed across several examination assignments rather than concentrated in one technical unit.
LADD, CAROLYN LOUISE is the busiest examiner with 1 pending matter. Because the busiest examiner accounts for only 1 matter, counsel should assess the applications individually while tracking consistency in claim strategy and responses across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
| WITHERSPOON, SIKARL A | 1 | 86.3% | -20.1% |
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18727848 | METHODS FOR TREATING AML-MRC AND MDS | WITHERSPOON, SIKARL A | — |
| 18294510 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | OH, TAYLOR V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269301 | METHODS OF TREATING MULTIPLE SCLEROSIS | SHIM, DAVID M. | 51d overdue |
| 18833076 | CRYSTALLINE FORM OR AMORPHOUS FORM OF MACROCYCLIC COMPOUND OR SALT OR SOLVATE THEREOF | LADD, CAROLYN LOUISE | — |
| 18294510 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | OH, TAYLOR V | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| 1625 | 1 |
| 1626 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833076 | CRYSTALLINE FORM OR AMORPHOUS FORM OF MACROCYCLIC COMPOUND OR SALT OR SOLVATE THEREOF | LADD, CAROLYN LOUISE | — | §103 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18727848 | METHODS FOR TREATING AML-MRC AND MDS | WITHERSPOON, SIKARL A | 1692 | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18294510 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | OH, TAYLOR V | 1625 | §102§112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18269301 | METHODS OF TREATING MULTIPLE SCLEROSIS | SHIM, DAVID M. | 1626 | §103 | Final Rejection | 51d overdue | Pending | Jun 23, 2023 |
| 17918557 | NOVEL MEDICAL USE OF MDM2 INHIBITORS | NOLAN, JASON MICHAEL | 1600 | §103DP | Final Rejection | — | Pending | Oct 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAscentage Pharma Group Corp Limited has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Carolyn Louise Ladd has the most, with 1 of Ascentage Pharma Group Corp Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
